共 66 条
[3]
Anti-Interleukin 23 Biologic Are Mostly Effective and Safe in Psoriatic Patients Who Failed Anti-Interleukin 17. A Real-Life, Retrospective 52-Week Experience
[J].
ACTAS DERMO-SIFILIOGRAFICAS,
2023, 114 (04)
:T363-T365
[10]
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial
[J].
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY,
2017, 76 (03)
:405-417